4 newer rulings cite the same tariff codes.
Classification can shift over time. Review the more recent rulings below before relying on this one.
The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk form, from Taiwan
Issued May 3, 2017 by U.S. Customs and Border Protection.
Cite this ruling
Copies to clipboardN2 N285338 (May 3, 2017)
Tariff classification
HTS codes: 2935.90.6000
Headings: 2935
Product description
Baricitinib is a Janus kinase inhibitor, which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes. Currently, Baricitinib, is an investigational drug that is undergoing phase III clinical trials for the treatment of rheumatoid arthritis.
CBP rationale
The applicable subheading for the Baricitinib in bulk form will be 2935.90.6000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs: Other.
Full text
N285338 May 3, 2017 CLA-2-29:OT:RR:NC:N2:238 CATEGORY: Classification TARIFF NO.: 2935.90.6000 Ms. Amy Liang Pharmaports LLC 1 E. Uwchlan Avenue, Suite 116 Exton, PA 19341 RE: The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk form, from Taiwan Dear Ms. Liang: In your letter dated April 13, 2017, on behalf of Chunghwa Chemical Synthesis and Biotech Co., you requested a tariff classification ruling. Baricitinib is a Janus kinase inhibitor, which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes. Currently, Baricitinib, is an investigational drug that is undergoing phase III clinical trials for the treatment of rheumatoid arthritis. The applicable subheading for the Baricitinib in bulk form will be 2935.90.6000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Sulfonamides: Other: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Baricitinib is not listed in the Pharmaceutical Appendix to the Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Tenapanor Hydrochloride (CAS No. 1234365-97-9) in bulk form, from Taiwan
The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk powder form, from Taiwan
The tariff classification of Sparsentan (CAS No. 254740-64-2) in bulk powder form, from China
The tariff classification of Baricitinib (CAS No. 1187594-09-7) in bulk powder form, from Taiwan
Follow N285338
Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.
One email per day at most. Confirm your address once, unsubscribe anytime.
Searching CBP rulings the smart way
Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.